Trends Shaping India Pharma: Next-Gen Therapies, Adjacencies, LOE Strategies And More

The arrival of an indigenous CAR-T cell therapy, a shot at GLP-1s and Parkinson’s disease, strides into adjacencies and an “easy revenue stream” formula for products set to lose exclusivity are some of the striking developments seen playing out in India. Industry leaders, including Cipla’s CEO, share their views with Scrip on some of the key trends in the first instalment of this two-part roundup.

Looking Ahead
Peaks, Troughs And Trends Defining India Pharma • Source: Shutterstock

The year gone by saw India Pharma Inc scale new peaks in terms of cutting-edge R&D advances but there were perilous valleys as well as quality issues hit hard, threatening to eclipse the industry’s reputation as the pharmacy to the world.

While a young Indian cell and gene therapy company, Immunoadoptive Cell Therapy (ImmunoACT), delivered the country’s first CAR-T cell therapy,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip